Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 12 September 2025, 12:20 HKT/SGT
Share:
    

Source: Eisai
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month

TOKYO, September 12, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the release of a concept movie and new content on the dedicated website for its “New Answers to Dementia” campaign, designed to increase corporate awareness.

In March 2025, Eisai launched a dedicated website (Japanese only) to share its commitment and ongoing efforts in pursuing “new answers” to dementia with a wider audience.

Japan’s “Basic Act on Dementia to Promote an Inclusive Society” designates September as “Dementia Month” and September 21 as “Dementia Day in line with globally recognized World Alzheimer’s Month and World Alzheimer’s Day.” To coincide with Dementia Month, when public awareness of dementia is high, Eisai has released a concept movie and published exclusive content on its designated website. The movie embodies Eisai’s belief in “Science, Courage, and Perseverance” in the ongoing pursuit of “new answers” for dementia. The content highlights the initiatives of companies and organizations across Japan that share Eisai’s commitment to supporting dementia patients.

Overview of Dedicated Website and its Content

Dedicated Website URL
https://www.eisai.co.jp/newanswer/

New Content

1) Concept Movie “History Begins with Belief”

Eisai embraces a mindset of having the “courage to step where no one dare go,” “perseverance to believe in our ability to succeed,” and “science that underpins our convictions.” With the principles of “Science, Courage, and Perseverance,” Eisai continues to deliver “new answers” for dementia care. To share this passion, Eisai produced a 120-second movie. More than 30 actual Eisai staff appear in the movie as employees, and it was filmed at Eisai’s own research facilities using genuine laboratory instruments and equipment.

Additionally, an interview with Eisai’s COO, Keisuke Naito, in which he shares the passion and idea behind the movie is currently available on Toyo Keizai Online.

URL https://toyokeizai.net/articles/-/895926

2) Showcase: “Our New Answer”

In Japan, countless businesses and organizations are continuously developing various “new answers.” This content highlights the initiatives of Eisai’s like-minded partners who are committed to creating “new answers” and building a society where dementia patients and their families can live their fullest lives.

Eisai's corporate concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as the human health care(hhc) concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. Within the dementia field, where it has long been focused as a leading pioneer, Eisai is committed not only to developing therapeutic medicines but also to creating a dementia ecosystem in collaboration with various partners, including other industries and local governments, that provides comprehensive support from prevention to care for patients, their families, and the people in the daily living domain, in order to realize a dementia-inclusive society where anyone can live their fullest life.

Eisai will continue to pursue “new answers” in partnership with dementia patients, their families, and our partners.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120 




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: